Skip to main content

Barclays Reaffirms Their Buy Rating on Elevance Health (ELV)

Tipranks - Tipranks - Wed Mar 4, 3:50AM CST

In a report released today, Andrew Mok CFA from Barclays maintained a Buy rating on Elevance Health, with a price target of $393.00.

Claim 70% Off TipRanks Premium

Mok CFA covers the Healthcare sector, focusing on stocks such as Brookdale Senior Living, Humana, and Acadia Healthcare. According to TipRanks, Mok CFA has an average return of -0.4% and a 51.00% success rate on recommended stocks.

Currently, the analyst consensus on Elevance Health is a Moderate Buy with an average price target of $389.07.

See Insiders’ Hot Stocks on TipRanks >>

Based on Elevance Health’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $49.75 billion and a net profit of $547 million. In comparison, last year the company earned a revenue of $45.44 billion and had a net profit of $418 million

Read More on ELV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).